-
HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets
Tuesday, May 29, 2018 - 2:44pm | 372Read More...G1 Therapeutics Inc (NASDAQ: GTHX), a clinical-stage biopharmaceutical company that focuses on novel oncology therapeutics, boasts three drug candidates that address "potential blockbuster" markets, according to H.C. Wainwright. The Analyst H.C. Wainwright's Edward White initiated...
-
Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial
Friday, April 6, 2018 - 7:50am | 372Read More...Incyte Corporation (NASDAQ: INCY), a biopharmaceutical company that focuses on developing medications for the treatment of cancer, announced Friday a disappointing update to a phase 3 trial. What Happened Incyte said its experimental therapy called epacadostat failed in a phase 3 trial called...
-
Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued
Wednesday, March 14, 2018 - 8:53am | 436Read More...Bluebird bio Inc (NASDAQ: BLUE), a clinical-stage biotechnology company that focuses on therapies for the treatment of severe diseases and cancer, released "highly encouraging" clinical data in late 2017, according to Janney. But that doesn't mean investors should be aggressive buyers...
-
Checkpoint Therapeutics Wins A New Bull As Company's 'Plan Is Quickly Coming Together'
Friday, December 8, 2017 - 10:42am | 386Read More...Checkpoint Therapeutics Inc (NASDAQ: CKPT), a nano-cap therapeutics company that focuses on developing anti-cancer agents, has lost more than half of its value over the past few months but some analysts are bullish on the longer-term picture. The Analyst H.C. Wainwright's Joseph Joseph...
-
Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug
Thursday, October 19, 2017 - 11:22am | 459Read More...The U.S. Food and Drug Administration approved Wednesday Gilead Sciences, Inc. (NASDAQ: GILD)'s therapy for the treatment of non-Hodgkin's Lymphoma (NHL) called YESCARTA. The announcement helped boost Gilead's stock higher by more than 1 percent Thursday, yet some on Wall Street aren't ready to...
-
Puma Biotech Makes Big Breakthrough In Breast Cancer Treatment
Monday, May 22, 2017 - 10:00am | 411Read More...Shares of Puma Biotechnology Inc (NASDAQ: PBYI) soared higher by more than 70 percent on Monday after the U.S. Food and Drug Administration posted briefing documents ahead of the regulatory body's review of Puma's PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage...
-
Today's Top Mover: HTG Molecular Soars 60%
Thursday, March 23, 2017 - 7:53am | 338Read More...Shares of HTG Molecular Diagnostics Inc (NASDAQ: HTGM) soared higher by more than 60 percent early Thursday morning after the molecular profiling company confirmed regulatory approval for its products in Europe. HTG Molecular announced that it has obtained CE marking in the European Union for its...
-
Everything We Know About Merck's Keytruda
Wednesday, March 8, 2017 - 2:22pm | 542Read More...Merck & Co., Inc. (NYSE: MRK)'s KEYTRUDA is a therapy used to combat a form of skin cancer called melanoma. It can also be used to treat a kind of lung cancer called non-small cell lung cancer. The U.S. Food and Drug Administration announced on Nov. 28, 2016, it has granted a Priority Review...
-
Transgemonic Up Another 33% Following Yesterday's 295% Run
Friday, January 13, 2017 - 8:38am | 300Read More...Transgenomic Inc (NASDAQ: TBIO), a nano-cap biotechnology engaged in advancing personalized medicine for the detection and treatment of cancer, skyrocketed higher by 295 percent Thursday. Transgenomic's stock gained $0.84 per share Thursday and closed at $1.12 after hitting an intra-day high of $1....
-
FDA Approves Clovis Oncology's Ovarian Cancer Treatment
Monday, December 19, 2016 - 11:53am | 381Read More...Shares of Clovis Oncology Inc (NASDAQ: CLVS) soared higher by more than 15 percent Monday after the U.S. Food and Drug Administration granted an accelerated approval for the company's PARP inhibitor rucaparib for the treatment of women with advanced ovarian cancer which will now be branded...
-
ZIOPHARM Announces Clinical Data On Brain Cancer Drug
Thursday, November 17, 2016 - 10:01am | 319Read More...ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) is a biopharmaceutical company dedicated towards developing a portfolio of cancer therapies through synthetic immuno-oncology. Ziopharm announced Thursday an update related to an ongoing trial of its AD-RTS-hil-12 + orally-administered veledimex that's...
-
Citi Sees 26% Upside In TESARO On The Strength Of Trial Data
Monday, October 10, 2016 - 10:07am | 419Read More...Shares of TESARO Inc (NASDAQ: TSRO) were trading higher by more than 12 percent early Monday morning after the company reported encouraging results from its niraparib Phase 3 NOVA clinical trial results. The trial was designed to assess the progression free survival rate among 553 patients...
-
Compugen Achieves Milestone Event With Bayer
Monday, April 18, 2016 - 1:10pm | 172Read More...Compugen Ltd. (NASDAQ: CGEN) announced on Monday it has achieved a first preclinical milestone for CGEN-15022 as part of a cancer immunotherapy agreement with Bayer. The companies entered into a collaboration and license agreement in 2013 for the development of anitbody-based cancer immune...
-
Spectrum Pharmaceuticals Gains 5% After Company Confirms FDA Review Of New Drug
Friday, February 19, 2016 - 12:03pm | 118Read More...Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) were trading higher by nearly 5 percent late Friday morning after the company announced that the U.S. Food and Drug Administration (FDA) has accepted its EOquin for New Drug Application (NDA) for review. EOquin (apaziquone for intravesical...
-
Clovis Oncology Issues Update On Rociletinib, Will Meet With FDA On April 12
Friday, February 12, 2016 - 11:09am | 189Read More...Clovis Oncology Inc (NASDAQ: CLVS) announced on Friday that the U.S. Food and Drug Administration has scheduled a date of April 12, 2016 to discuss a New Drug Application for its rociletinib therapy. Rociletinib is an investigational therapy for the treatment of patients with mutant epidermal...
